These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1518118)

  • 1. [Antimicrobial activity of cefetamet against fresh clinical isolates of Branhamella catarrhalis].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Apr; 45(4):359-63. PubMed ID: 1518118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antimicrobial activity of cefetamet against clinically isolated microbial strains collected from urban RTI patients].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y
    Jpn J Antibiot; 1992 Nov; 45(11):1451-9. PubMed ID: 1494228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types.
    Yeo SF; Livermore DM
    J Med Microbiol; 1994 Apr; 40(4):252-5. PubMed ID: 8151675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency of BRO β-lactamase and its relationship to antimicrobial susceptibility and serum resistance in Moraxella catarrhalis.
    Saito R; Nonaka S; Fujinami Y; Matsuoka S; Nakajima S; Nishiyama H; Okamura N
    J Infect Chemother; 2014 Jan; 20(1):6-8. PubMed ID: 24462416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan.
    Hsu SF; Lin YT; Chen TL; Siu LK; Hsueh PR; Huang ST; Fung CP
    J Microbiol Immunol Infect; 2012 Apr; 45(2):134-40. PubMed ID: 22154675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility and beta-lactamase characterization of Branhamella catarrhalis isolates from 1983/1984 and 1988.
    Christensen JJ; Keiding J; Bruun B
    APMIS; 1990 Nov; 98(11):1039-44. PubMed ID: 2123390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro effect of cefixime against 200 strains of Branhamella catarrhalis. Comparison with cefotaxime].
    Chardon H; Bellon O; Lagier E; Giraud E
    Presse Med; 1989 Oct; 18(32):1556-9. PubMed ID: 2530531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern.
    Fung CP; Yeo SF; Livermore DM
    J Antimicrob Chemother; 1994 Feb; 33(2):215-22. PubMed ID: 8182002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of cefpodoxime against Branhamella catarrhalis.
    Takenouchi T; Nishino T
    Microbiol Immunol; 1991; 35(12):1059-71. PubMed ID: 1808460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis.
    Esel D; Ay-Altintop Y; Yagmur G; Gokahmetoglu S; Sumerkan B
    Clin Microbiol Infect; 2007 Oct; 13(10):1023-5. PubMed ID: 17608812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Branhamella catarrhalis: incidence in pulmonary infections and determination of sensitivity to 5 antibiotics].
    Texier-Maugein J; Escoubas J; Fouche J; Mormede M
    Pathol Biol (Paris); 1988 May; 36(5):540-3. PubMed ID: 3136431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
    Nash DR; Flanagan C; Steele LC; Wallace RJ
    Antimicrob Agents Chemother; 1991 Jan; 35(1):192-4. PubMed ID: 1901696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of restriction endonuclease analysis of BRO beta-lactamases in clinical and carrier isolates of Moraxella catarrhalis.
    Köseoglu O; Ergin A; Hascelik G
    Scand J Infect Dis; 2004; 36(6-7):431-4. PubMed ID: 15307563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children].
    Köseoğlu O; Ergin A; Gürkan Aydin N; Hasçelik G
    Mikrobiyol Bul; 2004 Oct; 38(4):335-40. PubMed ID: 15700658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [beta-Lactamases of Branhamella catarrhalis and their phenotypic implications].
    Chaïbi EB; Mugnier P; Kitzis MD; Goldstein FW; Acar JF
    Res Microbiol; 1995; 146(9):761-71. PubMed ID: 8584798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.